RPL3

Large ribosomal subunit protein uL3 · P39023 · RPL3 on Sugi Atlas →

3,676 patent compounds predicted against RPL3, 1,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery	PHASE2	WITHDRAWN
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)	nan	COMPLETED
Evaluation of Serum Autophagic Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Individuals	nan	ENROLLING_BY_INVITATION
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC	nan	UNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPL3 binder may also engage these)

Protein	Name	Similarity
Q4R5Q0	—	1.000	Q4R5Q0 →
Q29293	—	1.000	Q29293 →
G1TL06	—	1.000	G1TL06 →
P39872	—	1.000	P39872 →
P21531	—	1.000	P21531 →
P50880	—	1.000	P50880 →
P22738	—	1.000	P22738 →
Q6BXM5	—	1.000	Q6BXM5 →
P27659	—	1.000	P27659 →
Q8NKF4	—	1.000	Q8NKF4 →
P35684	—	1.000	P35684 →
P59671	—	1.000	P59671 →
Q59LS1	—	1.000	Q59LS1 →
O96774	—	1.000	O96774 →
P34113	—	1.000	P34113 →
P14126	—	1.000	P14126 →
Q6CJR7	—	1.000	Q6CJR7 →
O16797	—	0.999	O16797 →
P49149	—	0.999	P49149 →
P17094	—	0.999	P17094 →
Q3SZ10	—	0.998	Q3SZ10 →
P40372	—	0.998	P40372 →
E9PWZ3	—	0.998	E9PWZ3 →
Q8SQI3	—	0.998	Q8SQI3 →
Q6FTJ2	—	0.998	Q6FTJ2 →
Q759R7	—	0.997	Q759R7 →
Q9NBK4	—	0.997	Q9NBK4 →
P36584	—	0.996	P36584 →
Q92901	—	0.995	Q92901 →
Q97BX7	—	0.993	Q97BX7 →